Abstract 561P
Background
Improved survival of kidney transplant recipients has led to an increased cancer risk, including colorectal cancer (CRC). We hypothesize that impaired immunosurveillance allows progression of sessile serrated lesions (SSL), leading to a higher incidence of immunogenic mismatch repair deficient (dMMR), but not mismatch repair proficient (pMMR) CRC.
Methods
The nationwide Dutch transplant, pathology, and cancer registries were linked by probabilistic matching to retrieve clinical data of all transplant patients between 2000-2022. A standardized incidence ratio (SIR) was calculated for CRC adjusted for age, sex, and incidence year. Mismatch repair (MMR) status was determined through immunohistochemistry and risk ratios (RR) were estimated. Premalignant lesions were identified within the Dutch CRC screening program. Kidney transplant patients were 1:4 matched to controls based on age, sex, and year of screening.
Results
20 181 kidney transplant patients were identified between 2000-2022 (Table). The mean recipient age was 48 years and 60% were male. 218 tumors were observed, resulting in a SIR of 1.11 (95% CI: 0.96-1.26). In the 162 transplant patients in which MMR status was determined, dMMR occurred more frequently compared to the general population, RR 2.1 (95% CI: 1.6-2.7). Polyps were identified in 488 kidney transplant patients and matched to 1952 patients without kidney transplantation. SSL with dysplasia occurred more often in the transplantation cohort, RR 2.3 (95% CI: 1.3-3.9).
Table: 561P
Incidence of CRC
CRC | ||
Transplantation cohort | Control | |
Total no. of people | 20 181 | Population (16.6 mln.) |
Observed and expected tumors | 218 (observed) | 197 (expected) |
dMMR/total tumors | 45/162 (28%) | 5640/42 982 (13%) |
Stage I | 9/37 (24%) | 1214/9405 (13%) |
Stage II | 14/36 (39%) | 2138/9635 (22%) |
Stage III | 10/35 (29%) | 1839/15 370 (12%) |
Stage IV | 12/45 (27%) | 449/8572 (5%) |
Stage unknown | 0/9 | - |
Premalignant lesions (2015-2022) | ||
Total no. of people | 488 | 1965 |
Total no. of findings | 1336 | 5181 |
Adenoma | 1099 | 4050 |
Serrated polyps | 237 | 1131 |
Type of serrated polyps | ||
Hyperplastic | 172 (73%) | 748 (66%) |
SSL | 61 (26%) | 351 (31%) |
Traditional serrated adenoma | 4 (1.6%) | 32 (2.8%) |
Dysplasia | ||
SSL with dysplasia | 15 (25%) | 38 (8%) |
SSL without dysplasia | 46 (75%) | 313 (92%) |
Conclusions
This population-wide study suggests an increased risk to develop dMMR CRC, in all stages, after kidney transplantation but not pMMR CRC. Furthermore, we show an increased incidence of dysplasia in SSL, in which dMMR frequently occurs. This illustrates that unchecked immunosurveillance in transplant patients is clinically apparent in precancerous and cancerous lesions. These findings could change the manner of CRC screening and management of kidney transplant patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
Has not received any funding.
Disclosure
M. Koopman: Financial Interests, Institutional, Advisory Board, advisory board and speaker: Pierre Fabre; Financial Interests, Institutional, Advisory Board: MSD, Bayer; Financial Interests, Institutional, Advisory Board, Advisory Board, speaker: Servier; Financial Interests, Institutional, Invited Speaker: Merck, Bristol Myers Squibb; Financial Interests, Institutional, Trial Chair: Servier; Financial Interests, Institutional, Research Grant: Servier, Roche, Bayer, Bristol Myers Squibb, Merck, Personal Genomics Diagnostics, Sirtex, Pierre Fabre; Financial Interests, Institutional, Funding: Pierre Fabre, Amgen, Nordic Pharma, Novartis, Merck, Servier, Bristol Myers Squibb; Non-Financial Interests, Leadership Role, vice-chair of DCCG: Dutch Colorectal Cancer Group; Non-Financial Interests, Advisory Role, Member of KWF scientific board: KWF; Non-Financial Interests, Other, ESMO faculty member for the Gastro-Intestinal Tumours – colorectal cancer: ESMO; Non-Financial Interests, Advisory Role, expert member of committee “regie op registers dure geneesmiddelen” ZINNL: ZiNNL; Non-Financial Interests, Advisory Role, CRC expert on Kanker.nl platform for answering online CRC questions of CRC (non) patients: Patient respresentative organisation (Kanker.nl); Non-Financial Interests, Leadership Role, chair of RWD & DH working group: ESMO; Other, PI of the Dutch Prospective Colorectal Cancer Cohort study: PLCRC project. G.M. Bol: Financial Interests, Institutional, Research Grant: Bayer, Pierre Fabre, Terumo. All other authors have declared no conflicts of interest.
Resources from the same session
601P - Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH
Presenter: Yaqi Wang
Session: Poster session 10
602P - Brazil-TNT: A randomized phase II trial of neo-adjuvant chemoradiation followed by FOLFIRINOX vs chemoradiation for stage II/III rectal cancer
Presenter: Diogo Bugano Diniz Gomes
Session: Poster session 10
604P - Overall and progression-free survival of patients with metastatic colorectal cancer: A real-world prospective, longitudinal cohort study on the continuum of care (PROMETCO)
Presenter: Miriam Koopman
Session: Poster session 10
605P - First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort
Presenter: HELENA OLIVERES
Session: Poster session 10
606P - Regional lymph nodes (N+ vs N0) in metastatic colorectal cancer
Presenter: Emerik Osterlund
Session: Poster session 10
608P - Resectability of colorectal liver metastases (CLM) with aflibercept plus FOLFIRI: Results from a prospective French cohort
Presenter: René Adam
Session: Poster session 10
609P - The impact of surgical invasiveness on the efficacy of mFOLFOX6 in resected colorectal liver metastasis: An exploratory analysis of JCOG0603
Presenter: Yasuyuki Takamizawa
Session: Poster session 10
610P - Predicting benefit from FOLFOXIRI plus bevacizumab versus FOLFOX/FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer
Presenter: Marinde Bond
Session: Poster session 10
611P - SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
Presenter: Rui-Hua Xu
Session: Poster session 10